Nanobiotix [NASDAQ: NBTX] Shares Corporate Update and Underlines Key 2022 Milestone Targets

Nanobiotix S.A. [NASDAQ: NBTX] has disclosed a corporate update and also underscored key priorities and expected development achievements for 2022. The company confirmed that its priorities for the year centered around completing its in-progress studies, utilizing the opportunity to bring value by showing its registration strategy in immunotherapy, and growing the tumor-agnostic, combination-agnostic profile of NBTXR3 through its strategic partnerships.

Nanobiotix revealed that 2021 provided strong confirmation of the vast potential therapeutic advantages of NBTXR3 and the skills of the Nanobiotix team. NBTX confirmed that not only did its single-agent and combination development programs produce new data signifying radiotherapy-activated NBTXR3 may enhance clinical results for patients with either local or systemic disease, but the company was also able to introduce NANORAY-312, its global phase III registration study in head and neck cancer.

NBTX’s 2022 Corporate Priorities

The important priorities of the company for the year include work on the growth of NBTXR3’s global pipeline through current partnerships and/or the addition of new partnerships that can potentially contribute to complementary development and/or commercial capabilities. It is also planning to further line up resources and capital distribution with strategic priorities and improve operating efficiencies.

Furthermore, the main priority of the company for the year is to focus company-led development efforts on the completion of NANORAY-312. NBTX also intends to continue to promote a company culture of innovation, integrity, accountability, transparency, and inclusion.

NBTX’s 2022 Development Pipeline Objectives

The development pipeline objectives of NBTX for 2022 include focusing on NBTXR3 global commercial registration through NANORAY-312. Its objectives include increasing assessment of NBTXR3 safety and feasibility to additional solid tumor indications and therapeutic combinations outside of Company-led pathways through partners.

In addition, the company also disclosed that it projected that it had around €83.9 million in cash, cash equivalents, and investments, compared to €119.2 million as of December 31, 2020.